Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer

OBJECTIVE: The recurrence or progression under endocrine therapy in hormone receptor-positive (HR+) advanced breast cancer (ABC) remained a critical clinical challenge. Chidamide is an oral subtype-selective histone deacetylase (HDAC) inhibitor with multiple functions in tumor growth inhibition and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qingyuan, Wang, Tao, Geng, Cuizhi, Zhang, Yue, Zhang, Jinwen, Ning, Zhiqiang, Jiang, Zefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328505/
https://www.ncbi.nlm.nih.gov/pubmed/30700929
http://dx.doi.org/10.21147/j.issn.1000-9604.2018.06.05

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328505/
https://www.ncbi.nlm.nih.gov/pubmed/30700929
http://dx.doi.org/10.21147/j.issn.1000-9604.2018.06.05

Ejemplares similares